<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00647218</url>
  </required_header>
  <id_info>
    <org_study_id>VCC BRE 9936</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VICC-BRE-9936</secondary_id>
    <nct_id>NCT00647218</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer</brief_title>
  <official_title>A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and&#xD;
      radiation therapy before surgery may make the tumor smaller and reduce the amount of normal&#xD;
      tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells&#xD;
      that remain after surgery.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving paclitaxel together with radiation&#xD;
      therapy works in treating patients undergoing surgery for stage II or stage III breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the efficacy of paclitaxel and concurrent radiotherapy (as measured by&#xD;
           pathologic response rates) in patients with stage II or III breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the toxicities of this treatment regimen.&#xD;
&#xD;
        -  Correlate paclitaxel-induced tumor response with local recurrence-free survival, distant&#xD;
           disease-free survival, and overall survival.&#xD;
&#xD;
        -  Evaluate protein expression profiles by mass spectrometry in biopsy material and blood&#xD;
           specimens collected before and after treatment with paclitaxel.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Neoadjuvant chemotherapy: Patients receive paclitaxel IV over 3 hours on day 1.&#xD;
           Treatment repeats every 21 days for 3 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Chemoradiotherapy: Beginning 3-4 weeks after completion of neoadjuvant chemotherapy,&#xD;
           patients receive paclitaxel IV over 1 hour twice weekly and undergo radiotherapy once&#xD;
           daily, 5 days a week, for 6½ weeks.&#xD;
&#xD;
        -  Surgery: At 6-8 weeks after completion of chemoradiotherapy, patients undergo surgical&#xD;
           resection (e.g., modified radical mastectomy or lumpectomy and axillary node&#xD;
           dissection).&#xD;
&#xD;
        -  Adjuvant chemotherapy: Beginning 4-6 weeks after surgery, patients receive doxorubicin&#xD;
           hydrochloride IV over 20 minutes and cyclophosphamide IV over 1 hour on day 1. Treatment&#xD;
           repeats every 3 weeks for 4 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Hormonal therapy: After completion of adjuvant chemotherapy, patients with estrogen&#xD;
           receptor- and/or progesterone receptor-positive tumor receive hormonal therapy at the&#xD;
           discretion of the treating physician.&#xD;
&#xD;
      Patients undergo blood and tissue sample collection periodically to analyze changes in cell&#xD;
      cycle by flow cytometry; antibody assays; kinase assays for cyclin B1/CDC2; genetic assays&#xD;
      for p53, p21, and other molecular markers; and protein expression assays by mass&#xD;
      spectrometry.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>9 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity paclitaxel and radiation</measure>
    <time_frame>at 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of tumor response with local recurrence-free survival, distant disease-free survival, and overall survival</measure>
    <time_frame>at time of disease progression or death by any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein expression profiles as measured by mass spectrometry before and after treatment with paclitaxel</measure>
    <time_frame>Baseline and 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-operative adjuvant therapy</intervention_name>
    <description>Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>None noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>None noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic surgical procedure</intervention_name>
    <description>Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>None noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy with concurrent Paclitaxel</intervention_name>
    <description>Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>None noted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormonal Therapy</intervention_name>
    <description>After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically documented invasive carcinoma of the breast*&#xD;
&#xD;
               -  Tumor ≥ 2 cm in greatest dimension (e.g., T2-4) and any nodal status (e.g.,&#xD;
                  N0-3), including locally advanced disease, as defined by the following criteria:&#xD;
&#xD;
                    -  Primary tumor ≥ 5 cm&#xD;
&#xD;
                    -  Tumor of any size with direct extension to the chest wall or skin&#xD;
&#xD;
                    -  Inflammatory breast cancer (T4d)&#xD;
&#xD;
                    -  Metastasis to ipsilateral internal mammary node&#xD;
&#xD;
                    -  Ipsilateral lymph nodes that are clinically fixed to each other or to other&#xD;
                       structures (N2) NOTE: *Diagnosis may be made by core or tru-cut biopsies&#xD;
&#xD;
          -  Measurable or evaluable tumor&#xD;
&#xD;
               -  Measurable disease is defined as any mass that can be reproducibly measured in&#xD;
                  two perpendicular dimensions&#xD;
&#xD;
               -  Evaluable disease is defined as any lesion visible by mammogram or palpable by&#xD;
                  physical exam that does not fit the above criteria of measurability&#xD;
&#xD;
          -  Planning to undergo breast conservation surgery&#xD;
&#xD;
          -  Willing to undergo AND is a candidate for radiotherapy, in the judgement of the&#xD;
             treating radiation oncologist&#xD;
&#xD;
          -  No evidence of distant metastatic disease (e.g., lung, liver, bone, brain)&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 45%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancies within the past 5 years, except curatively treated&#xD;
             nonmelanomatous skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No history of hypersensitivity reaction to products containing polysorbate 80 (Tween&#xD;
             80)&#xD;
&#xD;
          -  No serious medical illness that, in the judgment of the treating physician, places the&#xD;
             patient at risk&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior tamoxifen as chemoprevention allowed&#xD;
&#xD;
          -  No prior radiotherapy to the ipsilateral breast&#xD;
&#xD;
               -  Prior radiotherapy to the contralateral breast is allowed&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Bapsi Chakravarthy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Williamson Medical Center</name>
      <address>
        <city>Frankling</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson-Madison Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Baskin Cancer Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Lebonheur Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Cetner</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>A Bapsi Chakravarthy, MD</investigator_full_name>
    <investigator_title>Associate Professor; Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

